Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

Journal:

Nature Communications

Published:

2025-05-09

DOI:

10.1038/s41467-025-59210-6

Affiliations:

24

Authors:

24

Go to article

Institutions	Authors	Share
AstraZeneca China, China	3.000000	0.13
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.04
Harbin Medical University Cancer Hospital, China	1.000000	0.04
Liaoning Cancer Hospital and Institute, China	1.000000	0.04
Tongji Hospital (TJH), HUST, China	1.000000	0.04
The First Hospital of Jilin University, China	1.000000	0.04
The First Hospital of China Medical University, China	1.000000	0.04
Taipei Medical University Hospital (TMUH), TMU, Taiwan	1.000000	0.04
Taipei Veterans General Hospital (TPEVGH), Taiwan	1.000000	0.04
Henan Cancer Hospital, ZZU, China	1.000000	0.04
Affiliated Cancer Hospital of Guangzhou Medical University, China	1.000000	0.04
Foshan First People's Hospital, China	1.000000	0.04
Linkou Chang Gung Memorial Hospital, Chang Gung Medical Foundation, Taiwan	1.000000	0.04
Nanchang People’s Hospital, China	1.000000	0.04
The Second People's Hospital of Neijiang, China	1.000000	0.04
Linyi Cancer Hospital, China	1.000000	0.04
Sir Run Run Shaw Hospital (SRRSH), Zhejiang University School of Medicine, China	1.000000	0.04
Affiliated Hospital of Hebei University, HBU, China	1.000000	0.04
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.04
AstraZeneca United States, United States of America (USA)	1.000000	0.04
Hubei Cancer Hospital (HBCH), China	0.500000	0.02
Tongji Medical College, HUST, China	0.500000	0.02
The Institute of Cancer Research (ICR), United Kingdom (UK)	0.500000	0.02
The Royal Marsden Hospital - London, The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	0.500000	0.02

Interested in Oncology and Carcinogenesis?